Brief: Akari Therapeutics Announces Presentation Of Case Study From Phase 3 Part A Clinical Trial Of Nomacopan
21/02/2023 13:39
Feb 21 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS ANNOUNCES PRESENTATION OF A CASE STUDY
FROM
PHASE 3 PART A CLINICAL TRIAL OF NOMACOPAN IN PEDIATRIC HSCT-TMA
AS A LATE-BREAKER AT THE TRANSPLANTATION & CELLULAR THERAPY
TANDEM MEETINGS
Source text for Eikon: ID:nGNX15dyGm
Further company coverage: AKTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics